UCB sues dozen drugmakers to stop generics of Vimpat; Novartis recalls some vaccines; Pharma employees crave flexible work schedules;

@FiercePharma: CEO Joe Jimenez figures Novartis can grow "slightly faster than the market" in China: Report | Follow @FiercePharma

 @EricPFierce: BMS, Pfizer say FDA to review Eliquis for new use. Yesterday's story | Follow @EricPFierce

 @CarlyHFierce: Vivus urges shareholders to vote as meeting nears; First Manhattan trying to instate 9 board members. ICYMI yesterday | Follow @CarlyHFierce

> The FDA says Novartis ($NVS) is voluntarily recalling one lot of its MENVEO meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM-197 conjugate vaccine because of an excess level of moisture in vials. Release

> UCB has sued more than a dozen drugmakers--including Novartis' generic unit Sandoz and Actavis ($ACT) for infringing its patent with their plans to make a generic version of its epilepsy medicine Vimpat. Story

> Dr. Reddy's Laboratories has launched Decitabine for Injection (50 mg), a generic of the cancer drug Dacogen, in the U.S. Release

> India's Sun Pharmaceutical Industries says the FDA has given it approval to make a generic version of Prandin, a Novo Nordisk ($NVO) diabetes drug. Story

> Some New York schools are making it possible for students to get Teva Pharmaceutical Industries' ($TEVA) morning-after contraceptive. Story

Medical Device News

@FierceMedDev: Arch, a wound care device startup, raises $7.3M. Item | Follow @FierceMedDev

 @MarkHFierce: So, which med tech companies are facing FDA warning letters this week? Roundup | Follow @MarkHFierce

@DamianFierce: Edwards prevailed in the latest round of its heart valve patent dispute with Medtronic. Report | Follow @DamianFierce

> Medtronic falls to Edwards in German patent spat. Article

> PIP breast implant scandal a boon to U.K. company. Report

> Boston Scientific launches catheter as patent suit pends. Story

> Health insurance cost-cutting climate hampers new devices. Article

Biotech News

@FierceBiotech: ICYMI yesterday: The 2013 biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce: Afatinib OK'd for lung cancer. To be sold as Gilotrif? Sounds like a character in Lord of the Rings. FDA release | Follow @JohnCFierce

@RyanMFierce: Mitsubishi to snap up vaccine developer Medicago in $357M deal. News | Follow @RyanMFierce

 @EmilyMFierce: In case you missed it yesterday: Senate committee approves funding increase for NIH in FY 2014. Article | Follow @EmilyMFierce

> New rules push drug trials out of India. Item

> Agios Pharma sets terms for closely watched biotech IPO. Article

> In hot biotech market, personalized drugs rise to the top. Story

> Aveo hit with SEC subpoena on tivozanib after FDA slap-down. Report

And Finally... A new study from HR firm Randstad found that pharma employees looking for perks are most interested in flexible work arrangements and reduced hours, followed by bonuses and company investments in professional development. Release

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.